Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | GPR3 | P46089 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507335 | 1.00 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| Quinolin-4-Amine SCHEMBL6416991 | 0.83 | NCF1 (0.60) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL377796 | 0.77 | TNKS2 (1.00) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL29650180 | 0.77 | TNKS2 (1.00) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL2084671 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL31169726 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL6827495 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL1193735 | 0.75 | KDM4E (1.00) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL31688848 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 | |
| SCHEMBL555407 | 0.75 | CYP1A2 (0.62) | CYP1A2TNKS2CYP2C19KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371354-A | Method for preparing 4-amino-2-quinolinone compounds by catalyzing cyclization of 1, 6-dinitrile with visible light | 浙江工业大学 | 2025-01-28 | — | — | CN | claimed |
| CN-118908891-A | Preparation method of 4-amino-2-quinolinone compound | 浙江广厦建设职业技术大学 | 2024-11-08 | — | — | CN | claimed |
| CN-113754584-B | Synthesis method and anticancer activity of 4-amino dihydroquinolinone compound | 河南师范大学 | 2023-07-21 | — | — | CN | claimed |
| CN-113754584-A | Synthesis method and anticancer activity of 4-aminodihydroquinolinone compounds | 河南师范大学 | 2021-12-07 | — | — | CN | claimed |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | PURDUE RESEARCH FOUNDATION | 2020-11-05 | — | — | US | claimed |
| EP-2234642-B1 | METHOD OF INCREASING IMMUNOLOGICAL EFFECT | IRX THERAPEUTICS INC (US) | 2017-09-27 | — | — | EP | claimed |
| EP-1998811-B1 | IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS | IRX THERAPEUTICS INC (US) | 2012-10-17 | — | — | EP | claimed |
| EP-1558254-B1 | USE OF 4-AMINOQUINOLINES COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS OF THE EYE | RAUT RAJEEV (IN) | 2010-12-15 | — | — | EP | claimed |
| US-7731945-B2 | Administering an exogenous antigen and an adjuvant of a NCM+thymosin alpha 1; inducing production of naive T cells and restoring T cell immune response; treating a cancer in a severely immune suppressed patient | IMMUNO-RX, INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-1558254-A2 | A PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINOQUINOLINES COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS OF THE EYE, COMPOSITIONS RESULTING THEREFROM | Raut, Rajeev (IN) | 2005-08-03 | — | — | EP | claimed |
| EP-0789588-B1 | METHOD FOR MAKING A MEDICAMENT FOR TREATING SECONDARY IMMUNODEFICIENCY | UNIV SOUTH FLORIDA (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003097025-A2 | A PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINOQUINOLINES COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISORDERS OF THE EYE AND COMPOSITIONS RESULTING THEREFROM | RAUT RAJEEV (IN) | 2003-11-27 | — | — | WO | claimed |
| US-20030216431-A1 | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV (IN) | 2003-11-20 | — | — | US | claimed |
| EP-0789588-A4 | METHOD FOR MAKING A MEDICAMENT FOR TREATING SECONDARY IMMUNODEFICIENCY | UNIV SOUTH FLORIDA (US) | 2001-11-28 | — | — | EP | claimed |
| US-5707931-A | 4-amino-2-quinolinone derivatives | KOREA RESEARCH INTSITUTED OF CHEMICAL TECHNOLOGY (KR) | 1998-01-13 | — | — | US | claimed |
| US-5698194-A | CYTOKINE MIXTURE CONTAINING INTERLEUKINS | UNIVERSITY OF SOUTH FLORIDA (US) | 1997-12-16 | — | — | US | claimed |
| EP-0789588-A1 | METHOD FOR MAKING A MEDICAMENT FOR TREATING SECONDARY IMMUNODEFICIENCY | UNIVERSITY OF SOUTH FLORIDA (US) | 1997-08-20 | — | — | EP | claimed |
| WO-1996015808-A1 | METHOD FOR MAKING A MEDICAMENT FOR TREATING SECONDARY IMMUNODEFICIENCY | UNIVERSITY OF SOUTH FLORIDA (US) | 1996-05-30 | — | — | WO | claimed |
| EP-0707569-A1 | 4-AMINO-2-QUINOLINONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-04-24 | — | — | EP | claimed |
| WO-1995000488-A1 | 4-AMINO-2-QUINOLINONE DERIVATIVES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216431-A1 | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | IL5, IL1B, IL4 | CYP1A2 439/4885TNKS2 1349/4885CYP2C19 700/4885 |
| US-20200345737-A1 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | SYK, BTK, MERTK | CYP1A2 4013/4885TNKS2 305/4885CYP2C19 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.